This trial is evaluating whether dTRA will improve 1 primary outcome and 11 secondary outcomes in patients with Coronary Angiography (CAG). Measurement will happen over the course of 24 hours post-cardiac catheterization.
This trial requires 62 total participants across 2 different treatment groups
This trial involves 2 different treatments. DTRA is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.
As a measure of radial artery intimal medial thickness, the intimal-medial thickness of the RAD seems to be a useful method for evaluating blood vessel stenosis.
Radial artery intima-media thickness increases with advancing age even after accounting for blood pressure. There may also be a genetic defect, but the exact mechanism is not known.
Radial artery IMT may be of value for identifying a higher incidence of arterial disease and future diabetes in subjects with diabetes mellitus but without evident vascular disease.
Despite recent advances in therapies, IMT still cannot be cured. Future research is required to address other intima contributors to CVD, such as lipid deposition and subendothelial collagen deposition. Future trials will need to be much longer term to evaluate if IMT is a predictive marker of long-term prognosis of atherosclerotic disease requiring clinical intervention in conjunction with IMT.
Most data are collected by examining radiology reports for RA intima thickness. Results from a recent clinical trial presented here show the importance of considering a population as a whole, compared to a particular population, to examine the magnitude of intimal thickness over time.
There was no significant difference in IOMT change between the patients who received Dtra or the patients who received the placebo, despite an increase in hs-CRP and a decrease in the mean IOMT values. Considering the results and the high cost of Dtra (US$12,000 per patient per year), Dtra appears to be uneconomical for use in the treatment of atherosclerotic lesions.
Measure of dtra can prove to be invaluable as a clinically important test for early detection of atherosclerotic disease. Clinicians should make use of this simple, inexpensively available test. Dtra is not only highly sensitive to the presence of atherosclerotic disease and is sensitive to the severity of these events. Measurement of dtra can be performed rapidly. Further, a high level of agreement exists between experienced clinicians in diagnosing atherosclerotic disease and has been validated prospectively in patients examined on clinical protocols. To further our understanding of the test, we have examined the relationship between dtra and intimal thickness of the brachial artery.
The findings from this study illustrate the potential for Dtra to be a useful intervention for reducing IMT in people with RA. The small improvements in HRQoL experienced by the study participants should be considered in the context of the clinical and epidemiological significance of IMTs and their known effects on subsequent morbidity and mortality.
The majority of RA IMT was unrelated to atherosclerosis, but was related to intima thickness along the RA, suggesting that RA IMT likely represents systemic arterial disease rather than atherosclerosis of the RA.
The drepanolamine and diazepam groups experienced more adverse symptom scores (headache, somnolence) and more adverse GI and CNS side effects (fatigue, nausea or vomiting, abdominal pain, dizziness) than the placebo group, indicating a greater incidence of these side effects. It is important to recognize these side effects at the earliest opportunity when using a non-pharmacological treatment such as DTRA.
RIMT is a simple and useful method to estimate the risk of MI formation in patients with DM. This method permits the identification of those patients most at high risk and the identification of treatment strategies aimed to reduce the risk of coronary heart disease and should be used along with other risk factors for CHD.